Sustained release ophthalmological device and method of making and using the same

Abstract

An ophthalmological implant including a layer of pharmaceutical agent and an overlying layer of a bioerodible material, a biodegradable material a bioavailable material or a mixture thereof.

Description

CLAIM OF BENEFIT OF FILING DATE [0001] The present application claims the benefit of the filing date of U.S. Provisional Application Ser. Nos. 60 / 349,465, filed Jan. 18, 2002, and 60 / 397,698, filed Jul. 22, 2002, the contents of which are hereby incorporated by reference for all purposes.TECHNICAL FIELD [0002] The present invention relates to ophthalmologic implants and more particularly to implants that incorporate a sustained release pharmaceutical agent, such as a steroid, an antibiotic, an anti-inflammatory agent, antiglaucomatous, or a combination thereof, BACKGROUND OF THE INVENTION [0003] Currently available delivery systems for intraocular therapeutics are generally limited to 1) drops, which carry issues of expense, inconvenience, patient noncompliance (by overuse, underuse, or inappropriate frequency of use) as well as difficulty for delivery of the medications by certain patients (especially those with arthritic conditions who cannot manipulate the vials properly); 2) inj...

AI Technical Summary

Benefits of technology

"The present invention provides an improved ophthalmologic implant that has attached thereto a pharmaceutical agent in a sustained release medium for implantation into a human eye. The implant may be fabricated in a number of different ways, but in a highly preferred embodiment, it includes a plurality of layers, at least one of which degrades, erodes or otherwise diminishes by becoming bioavailable over time to release an underlying layer including a pharmaceutical agent. The pharmaceutical agent may be dispersed in sustained release medium material that is coated over a surface of an implant, impregnated into a space within the implant or combination thereof. The invention offers the advantage of eliminating the need or implant recipient to receive prolonged post-operative therapy with topically applied pharmaceutical agents, reducing post-operative prescription drug costs and associated health care needs."

Problems solved by technology

Currently available delivery systems for intraocular therapeutics are generally limited to 1) drops, which carry issues of expense, inconvenience, patient noncompliance (by overuse, underuse, or inappropriate frequency of use) as well as difficulty for delivery of the medications by certain patients (especially those with arthritic conditions who cannot manipulate the vials properly); 2) injections; and 3) bulky intravitreal implants placed within the vitreous cavity of the eye, requiring incisions in the eye and delicate manipulations of the vitreous gel.

Images